Research letter

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design

Subtitle: Vaccine effectiveness of Ad26.COV2.S in Brazil

Otávio T Ranzani, PhD^{1,2}, Rogério dos Santos Leite, MD³, Larissa Domingues Castilho, PT⁴, Crhistinne Cavalheiro Maymone Gonçalves, PhD^{4,5}, Geraldo Resende, MD⁴, Rosana Leite de Melo, MD⁶, Julio Croda, PhD^{5,7,8}

¹ Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain

² Pulmonary Division, Heart Institute (InCor), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina da Universidade de São Paulo, Brazil

³ Secretaria Municipal de Saúde de Corumbá, Corumbá, Brazil

⁴ Secretaria de Saúde do estado de Mato Grosso do Sul, Campo Grande, Brazil

⁵ Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil

⁶ Secretaria Extraordinária de Enfrentamento à Covid-19, Ministério da Saúde, Brasília, Brazil

⁷ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, USA

⁸ Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, Brazil

Correspondence to:

Prof Julio Croda,

Universidade Federal de Mato Grosso do Sul and Fundação Oswaldo Cruz,

julio.croda@fiocruz.br

Keywords

COVID-19; vaccine, Gamma variant; Ad26.COV2.S; test-negative study; case-control study; Brazil

Word count: 563

Abstract:

We used a test-negative design to estimate the vaccine effectiveness of Ad26.COV2.S (Janssen) against symptomatic COVID-19 and clinical outcomes in Mato-Grosso do Sul, Brazil. We analyzed 11,817 RT-PCR tests. The mean age was 37 (SD=17) years, 2,308 (20%) of individuals more or equal than 50 years and almost two-thirds of the population was Brown/Pardo. Adjusted effectiveness against symptomatic COVID-19 after 28 days of the single dose was 50.9% (95% CI, 35.5-63.0). Adjusted effectiveness against clinical outcomes was 72.9% (95% CI, 35.1-91.1) for hospitalization, 92.5% (95% CI, 54.9-99.6) for ICU admission, 88.7% (95% CI, 17.9-99.5) for mechanical ventilation and 90.5% (95% CI, 31.5-99.6) for death. Despite lacking precision on some estimates, a single dose of Ad26.COV2.S vaccine continues to protect specially for severe forms of COVID-19 in the context of new variants.

Introduction

Ad26.COV2.S (Janssen, Johnson & Johnson) is an adenoviral vaccine against COVID-19, but unlike all other vaccine platforms, it is administered in a single dose.¹ There is limited real-world effectiveness data for Ad26.COV2.S,^{2,3} and a need for more studies for this vaccine especially in the context of Gamma and Delta variants. We used a test-negative design to estimate the vaccine effectiveness of Ad26.COV2.S against symptomatic COVID19 and clinical outcomes in Mato-Grosso do Sul, a central-west state in Brazil with borders to Bolivia and Paraguay.

Methods

We analyzed data from 25-06-2021 to 30-09-2021 in Mato-Grosso do Sul state (~2.8 million inhabitants), Brazil. In Mato-Grosso do Sul, Ad26.COV2.S started to be distributed on 25-06-2021 by the national campaign program. Additionally, there was a massive campaign vaccination with Ad26.COV2.S in 13 municipalities that comprises the international borders. During June, 2021, Mato-Grosso do Sul faced a huge COVID-19 Gamma outbreak.⁴

We followed the same methodology as previously described regarding inclusion/exclusion criteria.^{5,6} Briefly, we included RT-PCR from adults residing in Mato-Grosso do Sul, collected within 10 days of symptoms onset, and excluded previous infected individuals. Our primary outcome is vaccine effectiveness after 28 days of the single dose against symptomatic COVID-19. We defined a symptomatic case as presenting at least two acute respiratory symptoms, as defined in the efficacy trial of Ad26.COV2.S.¹ Additionally, we analyzed effectiveness against hospital and ICU admissions, use of invasive mechanical ventilation and death.⁶

We estimated vaccine effectiveness as 1-OR from logistic regression models. We adjusted the models for age, sex, diabetes mellitus, renal, hepatic, neurologic, hematologic, cardiovascular and respiratory chronic diseases, obesity, immunosuppressed status and time (day of year). Age and day of year were modelled with a restricted cubic spline. We used the period 0-13 days after the single dose as a bias-indicator.^{5,6} All analyses were conducted in R statistical software version 4.0.3 (R Project for Statistical Computing). The study was approved by the Ethical Committee for Research of Federal University of Mato-Grosso do Sul (CAAE: 43289221.5.0000.0021).

Results

We analyzed 11,817 RT-PCR tests. The mean age was 37±17 years, 2,308 (20%) of individuals ≥50 years and almost two-thirds of the population was Brown/Pardo. The prevalence of chronic comorbidities was low, being most frequent Diabetes mellitus (2.5%)(**Table 1**).

Adjusted effectiveness against symptomatic COVID-19 after 28 days of the single dose was 50.9% (95% CI, 35.5-63.0). Adjusted effectiveness against clinical outcomes was 72.9% (95% CI, 35.1-91.1) for hospitalization, 92.5% (95% CI, 54.9-99.6) for ICU admission, 88.7% (95% CI, 17.9-99.5) for mechanical ventilation and 90.5% (95% CI, 31.5-99.6) for death. The bias-indicators showed increased risk during the period 0-13 days after single dose (**Table 2**).

Discussion

We observed an effectiveness of 51% after 28 days of a single dose of Ad26.COV2.S against symptomatic COVID-19 and higher protection against clinical outcomes. Our results should be interpreted with the following issues. We do not have sequencing of this sample, but Gamma was predominant and Delta was rapidly emerging during the study period in Brazil. We analyzed a short follow-up period, thus we cannot evaluate potential waning on effectiveness. The bias-indicator showed residual confounding, which can be explained by the extensive outbreak that was ongoing when the vaccination started, and could indicate that our effectiveness estimates are underestimated.⁵

Despite lacking precision on some estimates, a single dose of Ad26.COV2.S vaccine continues to protect specially for severe forms of COVID-19 in the context of new variants.

Acknowledgment

We are grateful to the National Immunization Program, Ministry of Health, Brazil, for the vaccine supply to cover the mass campaign in the 13 municipalities in the internal borders of Mato-Grosso do Sul.

Author Contributions: Dr Ranzani and Dr Croda had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Ranzani, Croda.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Ranzani.

Obtained funding: NA.

Administrative, technical, or material support: Leite, Castilho, Resende.

Supervision: Croda.

Conflict of Interest Disclosures: Dr Croda reported receiving grants from the NIH and Sanofi during the conduct of the study and personal fees from Pan American Health Organization outside the submitted work. No other disclosures were reported.

Funding/Support:

JC is supported by the Oswaldo Cruz Foundation (Edital Covid-19 – resposta rápida:

48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the

Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Daniel Henrique Tsuha for automating database linkage and Victor Bertollo Gomes Porto for advice on study design.

References

1. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
2. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1
3. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. *N Engl J Med*. 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362
4. Boletim Epidemiológico COVID-19 - Governo do Estado do Mato Grosso do Sul. Accessed October 14, 2021. <https://www.vs.saude.ms.gov.br/wp-content/uploads/2021/10/Boletim-Epidemiologico-COVID-19-2021.10.13.pdf>
5. Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *The Lancet Regional Health - Americas*. Published online July 2021:100025. doi:10.1016/j.lana.2021.100025
6. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. *BMJ*. Published online August 20, 2021:n2015. doi:10.1136/bmj.n2015

Table 1. Characteristics of the analyzed population

	Category	Overall	Test-negative	Test-positive
		11817	7589	4228
Age	Mean (SD), years	37.7 (17)	37.0 (17)	38.9 (17)
Sex, n (%)	Female	6181 (52.3)	4101 (54.0)	2080 (49.2)
	Male	5636 (47.7)	3488 (46.0)	2148 (50.8)
Self-reported race, n (%)*	White/Branca	3440 (35.6)	2192 (35.5)	1248 (35.7)
	Brown/Pardo	5631 (58.2)	3618 (58.5)	2013 (57.6)
	Black/Preta	323 (3.3)	201 (3.3)	122 (3.5)
	Yellow/Amarela	249 (2.6)	151 (2.4)	98 (2.8)
	Indigenous/Indígena	32 (0.3)	21 (0.3)	11 (0.3)
Chronic comorbidities, n (%)				
Diabetes mellitus	Yes	298 (2.5)	166 (2.2)	132 (3.1)
Renal	Yes	36 (0.3)	26 (0.3)	10 (0.2)
Cardiovascular	Yes	485 (4.1)	277 (3.7)	208 (4.9)
Respiratory	Yes	174 (1.5)	122 (1.6)	52 (1.2)
Imunodepressed status	Yes	75 (0.6)	58 (0.8)	17 (0.4)
Obesity	Yes	135 (1.1)	59 (0.8)	76 (1.8)
Liver	Yes	7 (0.1)	2 (0.0)	5 (0.1)
Neurologic	Yes	24 (0.2)	10 (0.1)	14 (0.3)
Hematologic	Yes	4 (<0.1)	2 (<0.1)	2 (<0.1)
Place of residence, n (%)	Other	4994 (42.3)	3207 (42.3)	1787 (42.3)
	Capital	6308 (53.4)	4061 (53.5)	2247 (53.1)
	Massive	515 (4.4)	321 (4.2)	194 (4.6)
From symptoms onset to RT-PCR	Median [p25-75], Days	4 [3, 5]	4 [3, 5]	4 [3, 5]
Hospital admission, n (%)	Yes	827/11782 (7.0)	349/7570 (4.6)	478/4212 (11.4)
ICU admission, n (%)	Yes	238/11700 (2.0)	82/7520 (1.1)	156/4180 (3.7)
Use of invasive mechanical ventilation, n (%)	Yes	166/11694 (1.4)	58/7522 (0.8)	108/4172 (2.6)
Death, n (%)	Yes	214/11586 (1.9)	75/7444 (1.0)	139/4142 (3.4)
From symptoms onset to hospitalization	Median [p25-75], Days	5 [2, 7]	3 [1, 6]	6 [3, 8]
From symptoms onset to death	Median [p25-75], Days	16 [7, 26]	10 [3, 19]	18 [11, 27]
Vaccination				
Vaccine status, n (%)	Unvaccinated	10655 (90.2)	6829 (90.0)	3826 (90.5)
	0-13 days after single dose	430 (3.6)	214 (2.8)	216 (5.1)
	14-27 days after single dose	373 (3.2)	258 (3.4)	115 (2.7)
	≥28 days after single dose	359 (3.0)	288 (3.8)	71 (1.7)
From vaccination to RT-PCR	Median [p25-75], Days	18 [11, 31]	23 [13, 35]	13 [9, 22]

* There are 2,142 missing values for self-reported race, equally distributed between test-negative and test-positive

Table 2. Adjusted vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes

	Adjusted OR (95 CI)	Adjusted VE (95% CI)
Symptomatic COVID19 (n=11,817)		
Unvaccinated		
0-13 days after single dose	1.56 (1.27 to 1.91)	-55.8% (-90.8 to -27.3)
14-27 days after single dose	0.73 (0.57 to 0.91)	27.4% (8.7 to 42.7)
≥28 days after single dose	0.49 (0.37 to 0.64)	50.9% (35.5-63.0)
Hospital admission (8,067)		
Unvaccinated		
0-13 days after single dose	1.37 (0.78 to 2.29)	-37.3% (-129.1 to 22.1)
14-27 days after single dose	0.67 (0.30 to 1.29)	33.5% (-29.1 to 69.8)
≥28 days after single dose	0.27 (0.09 to 0.65)	72.9% (35.1 to 91.1)
ICU admission (n=7,745)		
Unvaccinated		
0-13 days after single dose	1.08 (0.34 to 2.71)	-7.5% (-170.6 to 66.1)
14-27 days after single dose	0.44 (0.07 to 1.53)	56.0% (-52.8 to 93.1)
≥28 days after single dose	0.08 (0 to 0.45)	92.5% (54.9 to 99.6)
Use of invasive mechanical ventilation (n=7,697)		
Unvaccinated		
0-13 days after single dose	1.1 (0.28 to 3.23)	-10.3% (-222.9 to 72.2)
14-27 days after single dose	0.35 (0.02 to 1.75)	65.2% (-74.7 to 98.1)
≥28 days after single dose	0.11 (0 to 0.82)	88.7% (17.9 to 99.5)
Death (n=7,728)		
Unvaccinated		
0-13 days after single dose	1.71 (0.58 to 4.16)	-70.7% (-316.5 to 42.2)
14-27 days after single dose	0.51 (0.07 to 1.92)	48.9% (-92.3 to 92.5)
≥28 days after single dose	0.09 (0 to 0.68)	90.5% (31.5 to 99.6)

VE - vaccine effectiveness